Bayesian Capital Management, LP Delcath Systems, Inc. Transaction History
Bayesian Capital Management, LP
- $600 Million
- Q2 2025
A detailed history of Bayesian Capital Management, LP transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 13,300 shares of DCTH stock, worth $130,739. This represents 0.03% of its overall portfolio holdings.
Number of Shares
13,300Holding current value
$130,739% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding DCTH
# of Institutions
121Shares Held
13.3MCall Options Held
105KPut Options Held
38.7K-
Vanguard Group Inc Valley Forge, PA1.61MShares$15.8 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$7.99 Million0.25% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il803KShares$7.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA703KShares$6.91 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA570KShares$5.6 Million1.64% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $84.5M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...